Seeking Alpha

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis ...

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...
WAVY-TV

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024

FARMINGTON HILLS, Mich., and PITTSBURGH, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and ...
Seeking Alpha

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI ™ (phentolamine ophthalmic solution) 0.75% for the ...
Healio

FDA approves ophthalmic spray for mydriasis

Please provide your email address to receive an email when new articles are posted on . Eyenovia’s Mydcombi is a fixed-combination of tropicamide and phenylephrine administered as a spray for ...
Monthly Prescribing Reference

Fixed-Dose Combo Mydcombi Ophthalmic Spray Approved to Induce Mydriasis

Credit: Getty Images. MydCombi is a combination of tropicamide, an anticholinergic, and phenylephrine hydrochloride, an alpha-1 adrenergic receptor agonist. The Food and Drug Administration (FDA) has ...